Spyre Therapeutics
SYRE
SYRE
107 hedge funds and large institutions have $1.18B invested in Spyre Therapeutics in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 17 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
107
Holders Change
+4
Holders Change %
+3.88%
% of All Funds
1.56%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
29
Increased
47
Reduced
17
Closed
24
Calls
$61K
Puts
$35K
Net Calls
+$26K
Net Calls Change
-$50K
Top Buyers
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$85.6M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$47M |
| 3 |
BlackRock
New York
|
+$43.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$30M |
Top Sellers
| 1 |
YF
Yu Fan
|
-$16.4M |
| 2 |
Millennium Management
New York
|
-$12.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.48M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$6.14M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.85M |
